Evidence map›Paper›PMID 7935461›Full record

ArticleMolecular and cellular biology1994

Microinjection of the SH2 domain of the 85-kilodalton subunit of phosphatidylinositol 3-kinase inhibits insulin-induced DNA synthesis and c-fos expression.

B H Jhun, D W Rose, B L Seely, L Rameh, L Cantley, A R Saltiel, J M Olefsky

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Neuregulin 1-Beta cytoprotective role in AML 12 mouse hepatocytes exposed to pentachlorophenol.International journal of environmental research and public health · 2006
    Article
  6. Article
  7. Kinase activation through dimerization by human SH2-B.Molecular and cellular biology · 2005
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

B H JhunDepartment of Medicine, University of California, San Diego, La Jolla 92093.
D W Rose
B L Seely
L Rameh
L Cantley
A R Saltiel
J M Olefsky
University of California, San Diego · US

Funding

Metal Homeostasis in YeastR01GM041840 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALSPAUGH, ANDREW · 1989 to 2022
$6.5M
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEMR37DK033651 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 2000 to 2010
$6.1M
The Role of PI3K in Growth RegulationR01GM041890 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CANTLEY, LEWIS C. · 1990 to 2016
$4.1M
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEMR01DK033651 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 1986 to 2013
$2.2M
NIDDK NIH HHS DK 33651NIGMS NIH HHS GM 41840NIGMS NIH HHS R01 GM041890
6 · The paper itself

Abstract

We have investigated the functional role of the SH2 domain of the 85-kDa subunit (p85) of the phosphatidylinositol 3-kinase in the insulin signal transduction pathway. Microinjection of a bacterial fusion protein containing the N-terminal SH2 domain of p85 inhibited insulin- and other growth factor-induced DNA synthesis by 90% and c-fos protein expression by 80% in insulin-responsive rat fibroblasts. The specificity of the fusion protein was examined by in vitro precipitation experiments, which showed that the SH2 domain of p85 can independently associate with both insulin receptor substrate 1 and the insulin receptor itself in the absence of detectable binding to other phosphoproteins. The microinjection results were confirmed through the use of an affinity-purified antibody directed against p85, which gave the same phenotype. Additional studies were carried out in another cell line expressing mutant insulin receptors which lack the cytoplasmic tyrosine residues with which p85 interacts. Microinjection of the SH2 domain fusion protein also inhibited insulin signaling in these cells, suggesting that association of p85 with insulin receptor substrate 1 is a key element in insulin-mediated cell cycle progression. In addition, coinjection of purified p21ras protein with the p85 fusion protein or the antibody restored DNA synthesis, suggesting that ras function is either downstream or independent of p85 SH2 domain interaction.

Indexed as

AnimalsAntibodiesCell LineDNAGenes, fosHumansInsulinInsulin Receptor Substrate ProteinsMicroinjectionsMolecular WeightPhosphatidylinositol 3-KinasesPhosphoproteinsPhosphotransferases (Alcohol Group Acceptor)Protein ConformationProto-Oncogene Proteins c-fosProto-Oncogene Proteins p21(ras)AntibodiesDNAHRAS protein, humanInsulinInsulin Receptor Substrate ProteinsIRS1 protein, humanIrs1 protein, ratPhosphatidylinositol 3-KinasesPhosphoproteinsPhosphotransferases (Alcohol Group Acceptor)Proto-Oncogene Proteins c-fosProto-Oncogene Proteins p21(ras)Receptor, InsulinRecombinant Fusion Proteins

Identifiers

PMID7935461
PMCPMC359282
OpenAlexW1951853856

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.